| Literature DB >> 28591512 |
Douglas W Thomson1, Anne J Wagner1, Marcus Bantscheff1, R Edward Benson2, Lars Dittus1, Birgit Duempelfeld1, Gerard Drewes1, Jana Krause1, John T Moore2, Katrin Mueller1, Daniel Poeckel1, Christina Rau1, Elsa Salzer1, Lisa Shewchuk3, Carsten Hopf1, John G Emery4, Marcel Muelbaier1.
Abstract
The availability of high quality probes for specific protein targets is fundamental to the investigation of their function and their validation as therapeutic targets. We report the utilization of a dedicated chemoproteomic assay platform combining affinity enrichment technology with high-resolution protein mass spectrometry to the discovery of a novel nicotinamide isoster, the tetrazoloquinoxaline 41, a highly potent and selective tankyrase inhibitor. We also describe the use of 41 to investigate the biology of tankyrase, revealing the compound induced growth inhibition of a number of tumor derived cell lines, demonstrating the potential of tankyrase inhibitors in oncology.Entities:
Mesh:
Substances:
Year: 2017 PMID: 28591512 DOI: 10.1021/acs.jmedchem.7b00137
Source DB: PubMed Journal: J Med Chem ISSN: 0022-2623 Impact factor: 7.446